Edwards Lifesciences Corporation (EW) Balance Sheet

The retained earnings climb from $9.7B to $15.2B over the period indicates that profitability, not external financing, is driving equity growth. Total debt has remained essentially flat near $700M, so the expansion in assets reflects internal accumulation and some acquisition-related goodwill rather than borrowed capital. This pattern appears consistent with a business whose quality is improving, though investors should monitor whether asset growth continues to outpace the revenue base.

A debt-to-equity ratio this low suggests the company has no meaningful refinancing pressure and does not depend on credit markets to fund operations. Debt has been held nearly constant across all ten quarters, which points to a deliberate choice rather than a necessity-driven structure. The implication is that cash flow durability is not being mortgaged to service obligations, though the company's reliance on equity-funded growth may carry its own opportunity cost.

The step-up in goodwill between 2024Q2 and 2024Q3 corresponds with the acquisition activity visible in cash flows, and it now represents a material share of total assets. This raises the question of impairment exposure if the acquired structural heart or TMTT assets underperform. Net PP&E has grown steadily, consistent with the specialized manufacturing requirements of tissue valve production, which implies a business model that is asset-moderate rather than asset-light.

Current ratios well above 3 imply current assets dwarf current liabilities, leaving ample room to absorb working capital swings. Cash of roughly $3.1B provides a significant cushion relative to the company's operating cost base. The quarterly fluctuations in cash, however, suggest that liquidity is sensitive to timing of receivables and inventory, which warrants monitoring even though the absolute buffer remains strong.